Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
Get Alerts PFE Hot Sheet
Price: $28.00 +0.79%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
Revenue Growth %: -22.3%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
Revenue Growth %: -22.3%
Join SI Premium – FREE
Pfizer (NYSE: PFE) reports that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.
Axitinib, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which are receptors that can influence tumor growth, vascular angiogenesis, and progression of cancer.
Axitinib, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which are receptors that can influence tumor growth, vascular angiogenesis, and progression of cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biodexa Pharmaceuticals' (BDRX) MTX110 Shows Promise In Extending Life Expectancy
- Third Harmonic Bio (THRD) Appoints Geoff McDonough to its Board
- Emergent BioSolutions (EBS) Continues to Broaden Access, Awareness and Availability of NARCAN Nasal Spray
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!